COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2 (CORVIS)
Community Participants With COPD or Bronchiectasis and at Risk of Respiratory Viral Infections Including SARS-CoV-2: An Open-label, Multicentre Feasibility Study of an Inhaled Nitric Oxide Generating Solution (RESP301)
Sponsor: Thirty Respiratory Limited
Terminated
Study stopping criteria were met. A safety event has occurred which was classified as an SAE and was related to the study intervention.
Other terminated trials from Thirty Respiratory Limited
More terminations from Thirty Respiratory Limited
Listed as NCT04858451, this PHASE2 trial focuses on Bronchiectasis and COPD and remains terminated or withdrawn. Sponsored by Thirty Respiratory Limited, it has been updated 10 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Sep 2023 — May 2024 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Jan 2023 — Sep 2023 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Jan 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Sep 2021 — Jan 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Thirty Respiratory Limited
For direct contact, visit the study record on ClinicalTrials.gov .